MOTS-c dosage chart: how much MOTS-c per week clinics prescribe
Clinics commonly prescribe MOTS-c at 5,000 to 10,000 mcg (5–10 mg) per subcutaneous injection, 2 to 3 times a week, in cycles of 8 to 12 weeks; the range reported runs from 5,000 to 15,000 mcg (5–15 mg) per injection, and from every 5 days to 5 times a week. No trial has set a dose, and no completed study has given MOTS-c to people; one trial is recruiting.
Topic: The MOTS-c doses clinics publish, how a vial is reconstituted, and what has been studied under the name MOTS-c
Audience: Anyone comparing MOTS-c dose figures across clinics
Reading time: 8–10 minutes
MOTS-c and CB4211: a peptide and its analog
MOTS-c is a 16-amino-acid mitochondrial-derived peptide, encoded within the mitochondrial genome, studied for effects on insulin sensitivity and metabolic homeostasis. CB4211 is a separate, synthetic molecule — an engineered analog of MOTS-c developed by CohBar Inc., described in the company’s own materials as such, not as MOTS-c itself. FDA’s own evaluation of MOTS-c does not reference CB4211 at all, confirming that FDA does not treat CB4211’s trial data as evidence for MOTS-c either. The MOTS-c profile covers the mechanism and broader research context in more depth; this page keeps that molecule distinction visible throughout.
The clinic dosage chart comes first, then reconstitution, the one trial of MOTS-c itself and the CB4211 trial, labeled as a different molecule throughout. Animal and lab results are set out on the MOTS-c profile.
MOTS-c dosage chart: what clinics prescribe
No trial has set a MOTS-c dose, so the figures below are clinic practice, not trial results. Clinics commonly prescribe 5,000 to 10,000 mcg (5–10 mg) per subcutaneous injection, 2 to 3 times a week, in cycles of 8 to 12 weeks, often followed by a break of several weeks; the range reported runs from 5,000 to 15,000 mcg (5–15 mg) per injection, and from every 5 days to 5 times a week. That comes to 10,000 to 30,000 mcg (10–30 mg) a week at the common dose. Clinics schedule it in the morning before the first meal, or 30 to 60 minutes before exercise on training days.
| Clinic | Dose as published | Schedule and course |
|---|---|---|
| Live Vital | 5,000–10,000 mcg (5–10 mg) per injection | 2–3 times a week; 8–12 week cycles |
| Lamkin Clinic | 5,000 mcg (5 mg) per injection | 3–5 times a week; 8–12 weeks on, then 4–8 weeks off |
| MedRein Health | 5,000–15,000 mcg (5–15 mg) per injection | 2–3 times a week; 4–12 week cycles |
| Perfect B | 5,000 mcg (5 mg) per injection | Every 5 days, 4 injections over a 20-day cycle |
Each clinic is cited for its own protocol in the references, and the same chart, with the side effects and cautions clinics list, is on the MOTS-c profile. Clinics sell MOTS-c and AOD-9604 as separate products rather than as one blend; what they prescribe for each is on the AOD-9604 + MOTS-c profile.
How much bac water for 10mg MOTS-c?
The volume of bacteriostatic water sets the concentration, not the dose. With 2 mL in a 10 mg MOTS-c vial, each mL holds 5,000 mcg (5 mg); with 1 mL, each mL holds 10,000 mcg (10 mg).
The MOTS-c reconstitution calculator and the peptide dosage calculator work out how much bacteriostatic water to add to a research-grade vial and how many syringe units a given amount takes. Neither sets a dose.
The one recruiting trial of MOTS-c itself
FDA’s 2026 review found no published study in which a MOTS-c drug product was given to people. The human studies that exist measure the body’s own MOTS-c, after exercise or in disease; the one trial that gives MOTS-c itself is below.
MOTS-c for Improving Insulin Sensitivity — Prediabetes/Overweight/Obesity
NCT07505745Recruiting; no results posted
Design: Phase 2 trial testing MOTS-c for insulin sensitivity in adults with prediabetes and overweight or obesity.
Arms: 120 participants planned (estimated): MOTS-c or placebo, subcutaneous injection, fixed dose once daily for 12 weeks.
The only registered trial of MOTS-c itself — currently recruiting, with no efficacy or safety results posted yet.
The CB4211 trial: real data, different molecule
CB4211 — a MOTS-c Analog, Not MOTS-c Itself (Phase 1a/1b)
NCT03998514Completed, with a temporary suspension mid-trial; topline results only, with no peer-reviewed publication
Molecule: CB4211, CohBar Inc.'s own engineered analog of MOTS-c — described by the company's own materials as such, not MOTS-c itself.
Design: 3-part randomized, double-blind, placebo-controlled study of single and multiple ascending subcutaneous doses in healthy non-obese subjects and subjects with nonalcoholic fatty liver disease (NAFLD).
Arms: 88 participants (actual, per the registry) across ascending dose cohorts in Phase 1a, and 20 subjects with NAFLD in Phase 1b, receiving 25,000 mcg (25 mg) by subcutaneous injection once daily for 4 weeks versus placebo.
Endpoint reported: Phase 1b topline (August 2021 company announcement, not peer-reviewed): reported reductions in ALT and AST, a reduction in glucose, and a trend toward lower body weight after 4 weeks, versus placebo.
Adverse events reported: Phase 1a dosing was temporarily suspended on November 5, 2018 (per CohBar's own SEC 8-K filing) due to "mild injection site reactions that have been unexpectedly persistent" — described as painless subcutaneous bumps where some of the dose remained at the injection site. The trial resumed under an amended protocol and was later reported as safe and well tolerated.
Topline company data — a real, registered, completed trial, but its efficacy findings were never published in a peer-reviewed paper, and every finding here describes CB4211, an analog, not MOTS-c itself.
No published source derives the clinic figures from CB4211’s 25,000 mcg (25 mg) dose, which is a different molecule’s figure, not MOTS-c’s.
Is MOTS-c legal?
MOTS-c is not FDA-approved. FDA lists MOTS-c as nominated for 503A compounding and then withdrawn, and HHS’s draft Enforcement Discretion Policy of October 30, 2026 names it in Appendix A, so HHS does not intend to act against 503A pharmacies compounding injectable MOTS-c acetate under its conditions; clinics prescribe it. WADA bans it in sport.
- FDA: the 503A nomination proposed 5,000 and 10,000 mcg (5 and 10 mg) subcutaneous injections and was withdrawn; FDA evaluated MOTS-c on its own initiative, and for the July 23–24, 2026 advisory committee its staff concluded that “a balancing of the criteria weighs against MOTS-c free base or MOTS-c acetate being placed” on the 503A Bulks List. The committee voted to recommend it, according to ABC News; a committee vote is a recommendation to FDA, not a change in status.
- HHS: its draft Enforcement Discretion Policy lists MOTS-c in Appendix A, and Appendix B covers MOTS-c acetate in subcutaneous or intramuscular injectable dosage forms only. It is not FDA approval or a 503A listing; its ten conditions are in the report on the HHS peptide policy.
- Sport: WADA’s 2026 Prohibited List names MOTS-c under S4.4.1, as an AMPK activator, prohibited at all times.
- Research-grade vials: sold for laboratory use only, not for human use; a research-use label does not make a vial an approved or prescribed product.
FAQ
Is CB4211 the same thing as MOTS-c?
What happened in the CB4211 Phase 1 trial?
What is the MOTS-c trial that's currently recruiting?
Is MOTS-c taken daily?
How long is a MOTS-c cycle?
References
- ClinicalTrials.gov. MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity, NCT07505745. https://clinicaltrials.gov/study/NCT07505745
- ClinicalTrials.gov. A Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease, NCT03998514. https://clinicaltrials.gov/study/NCT03998514
- CohBar, Inc. CohBar Provides Update on CB4211 Clinical Trial. SEC Form 8-K exhibit, 2018-11-05. https://www.sec.gov/Archives/edgar/data/1522602/000121390018014875/f8k110518ex99-1_cohbar.htm
- Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443–454. PMID 25738459. https://pubmed.ncbi.nlm.nih.gov/25738459/
- U.S. Food and Drug Administration. FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23–24, 2026 — Evaluation of MOTS-c Bulk Drug Substances. https://www.fda.gov/media/193347/download
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- U.S. Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A and Appendix B, October 2026. https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf
- World Anti-Doping Agency. The Prohibited List 2026, S4.4.1: “Activators of the AMP-activated protein kinase (AMPK), e.g. … mitochondrial open reading frame of the 12S rRNA-c (MOTS-c).” https://www.wada-ama.org/en/prohibited-list
- Live Vital (Dr Pat Taylor), physician-led peptide practice. MOTS-c. Cited for its own protocol: 5,000–10,000 mcg (5–10 mg) by subcutaneous injection 2–3 times a week, in 8–12 week cycles. Read November 15, 2026. https://www.drpattaylor.com/peptides/mots-c
- The Lamkin Clinic, Edmond, Oklahoma; Brian Lamkin, DO. What Is MOTS-c Peptide Used For? Cited for its own protocol: 5,000 mcg (5 mg) per injection 3 to 5 times a week, 8 to 12 weeks on and 4 to 8 weeks off, in the morning or 30 to 60 minutes before exercise. Read November 15, 2026. https://lamkinclinic.com/what-is-mots-c-peptide-used-for/
- MedRein Health & Aesthetics, Southlake, Texas; Haritha Mikkilineni, MD. NAD+, MOTS-C & SS-31 Energy Peptides in Southlake. Cited for its own protocol: 5,000–15,000 mcg (5–15 mg) 2 to 3 times a week, in 4 to 12 week cycles. Read November 15, 2026. https://medreinhealth.com/blog/nad-mots-c-ss-31-energy-peptides-in-southlake-tx/
- Perfect B, Doral, Florida. MOTS-c dosage. Cited for its own protocol: 5,000 mcg (5 mg) every 5 days, 4 injections over a 20-day cycle, in the morning, fasted. Read November 15, 2026. https://www.perfectb.com/?p=21777
- Dr. Yonathan Daniel, ABC News. FDA advisers narrowly vote to add 6 peptides to a drug compounding list. What’s next? Published July 24, 2026; read November 12, 2026. Cited for the committee’s recommendation of MOTS-c: over the two-day hearing it voted to recommend that BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax be added to an approved list of ingredients that specialty pharmacies can use; the article gives no tally. https://abcnews.com/Health/fda-advisers-narrowly-vote-add-6-peptides-drug/story?id=135064915
Affiliate disclosure: Prof. Peptide earns a commission on purchases and sign-ups made through its links and codes, at no extra cost to the buyer. Commissions never decide which vendors are listed, how they are ranked or verified, or what Prof. Peptide concludes.
Related pages
- How Is Mazdutide Dosed? China's NMPA Label, Read DirectlyHow Is Mazdutide Dosed? China's NMPA Label, Read Directly.
- MOTS-c Calculator: Dosage & ReconstitutionMOTS-c reconstitution and dosage math — vial size, BAC water and syringe units, worked for real vendor vial sizes.
- Mounjaro Dosage: The FDA Label Schedule and What Clinics ReportMounjaro's FDA-approved dosing schedule, the SURPASS trials behind it, the boxed warning and adverse events from the label, and how research-grade tirzepatide relates…
- Guides — Practical Peptide Research ReferencesPractical reference guides for peptide research — injection technique, reconstitution math, syringe sizing, and research fundamentals.
Checked and updated
